Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development

WARREN, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announces its Artificial Intelligence effort, Tevogen AI, has joined Microsoft (Nasdaq: MSFT) for Startups. This partnership marks a significant milestone for Tevogen, providing unparalleled access to Microsoft’s extensive